Home » AdComm Shows Support for Celltrion’s Remicade Biosimilar
AdComm Shows Support for Celltrion’s Remicade Biosimilar
An FDA advisory committee last week gave Celltrion’s biosimilar candidate for Remicade a strong show of support, backing its approval for six different indications in a 21-3 vote.
The vote came as no surprise, as FDA briefing documents released ahead of the Arthritis Advisory Committee meeting recommended approval for CT-P13.
Much of the discussion hinged on whether the data presented was enough to justify CT-P13’s use for six conditions: rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, Crohn’s disease and ulcerative colitis.
Upcoming Events
-
14May
-
23May
-
30May
-
20Jun
-
21Oct